This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Menactra
Brand Name :
Menactra
Generic Name :
Polysaccharide Diphtheria Toxoid Conjugate Vaccine
Partner :
Sanofi
What is this drug and what is it used for?
Menactra®, is a vaccine. Vaccines are used to protect against infectious diseases.
Menactra®, Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine, is indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135. Menactra is approved for use in individuals 9 months through 55 years of age. Menactra does not prevent N meningitidis serogroup B disease.
How is this drug given?
Menactra is administered as a single 0.5 mL dose by intramuscularinjection, preferably in the anterolateral thigh or deltoid region depending on the recipient’s age and muscle mass.
Do not administer this product intravenously or subcutaneously.
Primary Vaccination:
• In children 9 through 23 months of age, Menactra is given as a 2-dose series at least three months apart.
• Individuals 2 through 55 years of age, Menactra is given as a single dose.
Booster Vaccination:
• A single booster dose may be given to individuals 15 through 55 years of age at continued risk for meningococcal disease, if at least 4 years have elapsed since the prior dose.